Trial Profile
RCT Of Oral Thalidomide And Capecitabine Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma (BCLC D)
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Thalidomide (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms OTCHCC
- 26 Sep 2011 New trial record